Last updated: August 1, 2026
Zontivity (vorapaxar sulfate) is an oral protease-activated receptor-1 antagonist developed by Merck for secondary prevention of atherothrombotic cardiovascular events. The FDA approved it in 2014 for patients with a history of myocardial infarction or peripheral arterial disease. Its commercial profile was weakened by intracranial bleeding risk, a narrow eligible population, competition from established antiplatelet agents, and limited evidence supporting broad adoption.
The pivotal TRA 2°P-TIMI 50 trial showed cardiovascular benefit in selected patients with prior myocardial infarction and peripheral arterial disease, but the overall benefit-risk profile excluded patients with prior stroke, transient ischemic attack, or intracranial hemorrhage. Zontivity has no active late-stage clinical development program and has limited current commercial relevance compared with generic clopidogrel, aspirin, ticagrelor, and newer antithrombotic strategies.
What is Zontivity and how does vorapaxar work?
Zontivity contains vorapaxar sulfate, a selective antagonist of protease-activated receptor-1, or PAR-1. PAR-1 is activated by thrombin and contributes to platelet activation.
| Attribute |
Zontivity |
| Active ingredient |
Vorapaxar sulfate |
| Drug class |
PAR-1 antagonist |
| Route |
Oral |
| Approved strength |
2.08 mg vorapaxar, equivalent to 2.5 mg vorapaxar sulfate |
| FDA approval |
May 8, 2014 |
| Original sponsor |
Merck & Co. |
| Approved use |
Reduction of thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial disease |
| Key pivotal trial |
TRA 2°P-TIMI 50 |
| Major safety limitation |
Intracranial and other serious bleeding |
| Contraindications |
Prior stroke, transient ischemic attack, intracranial hemorrhage, or active pathological bleeding |
Zontivity is administered once daily. It is generally used with background antiplatelet therapy, commonly aspirin and, in selected patients, clopidogrel.
What did the pivotal Zontivity clinical trial show?
The principal evidence came from TRA 2°P-TIMI 50, a randomized, double-blind, placebo-controlled cardiovascular-outcomes trial involving 26,449 patients with a history of myocardial infarction, peripheral arterial disease, or ischemic stroke.
The trial enrolled three clinical cohorts:
- Prior myocardial infarction.
- Peripheral arterial disease.
- Prior ischemic stroke.
The stroke cohort was stopped early because of excess intracranial hemorrhage. The FDA-approved indication excludes patients with a history of stroke or transient ischemic attack.
TRA 2°P-TIMI 50 results
| Population |
Main finding |
| Prior myocardial infarction |
Reduced cardiovascular death, myocardial infarction, or stroke compared with placebo |
| Peripheral arterial disease |
Reduced cardiovascular death, myocardial infarction, or stroke, with a marked reduction in peripheral limb events |
| Prior ischemic stroke |
Unacceptable intracranial bleeding risk; development in this population was discontinued |
| Overall safety |
Increased moderate or severe bleeding and intracranial hemorrhage |
In the prior-myocardial-infarction population, the primary endpoint occurred in approximately 9.3% of vorapaxar-treated patients versus 10.5% of placebo-treated patients. The hazard ratio was approximately 0.80. In the peripheral arterial disease population, vorapaxar reduced major cardiovascular events and peripheral revascularization or limb ischemic events, but the absolute benefit remained sensitive to bleeding risk and background therapy.
The trial established efficacy in selected secondary-prevention populations. It did not establish a favorable risk-benefit profile for patients with prior cerebrovascular disease.
What is the current clinical-trial status of Zontivity?
Zontivity has no active pivotal development program. The major clinical-development question has shifted from efficacy expansion to residual clinical utility in narrowly selected patients.
Completed and relevant studies
| Study or program |
Objective |
Status and commercial relevance |
| TRA 2°P-TIMI 50 |
Cardiovascular outcomes in prior MI, PAD, and stroke |
Completed; basis for FDA approval |
| LANCELOT-ACS |
Vorapaxar in acute coronary syndrome |
Completed; did not create a broad approved commercial indication |
| LANCELOT-CAD |
Vorapaxar in coronary artery disease |
Completed |
| Peripheral arterial disease analyses |
Limb-event reduction and cardiovascular outcomes |
Supported the PAD indication |
| Postmarketing safety studies |
Characterization of bleeding and real-world use |
Reinforced the narrow treatment population |
Zontivity’s clinical value is greatest in patients with prior myocardial infarction or symptomatic peripheral arterial disease who have high thrombotic risk and no history of stroke or transient ischemic attack. Its value declines sharply when bleeding risk is elevated or when the patient has a competing indication for another antithrombotic regimen.
What is the FDA regulatory status of Zontivity?
The FDA approved Zontivity under the traditional drug pathway in 2014. It is not a biologic and has no biosimilar pathway.
The FDA label limits use to patients with a history of myocardial infarction or peripheral arterial disease. The label carries a boxed warning for bleeding risk. Zontivity is contraindicated in patients with:
- Prior stroke or transient ischemic attack.
- Prior intracranial hemorrhage.
- Active pathological bleeding.
The FDA label also warns that bleeding risk increases with age, prior bleeding, concomitant anticoagulants, fibrinolytic agents, nonsteroidal anti-inflammatory drugs, and other antiplatelet drugs.
Zontivity is not indicated for primary prevention of cardiovascular disease and is not a replacement for emergency antithrombotic treatment in acute coronary syndrome.
What is the Orange Book status of Zontivity?
Zontivity is an FDA-approved small-molecule product that would ordinarily be subject to abbreviated new drug application, or ANDA, competition after relevant regulatory exclusivity and listed-patent barriers expired.
The commercial importance of Orange Book protection has declined because the product has limited market demand and because several core composition and use protections have reached or approached the end of their effective life. The relevant patent analysis must distinguish among:
- Composition-of-matter protection for vorapaxar.
- Salt and crystalline-form protection.
- Pharmaceutical-composition protection.
- Methods of reducing cardiovascular or limb events.
- Manufacturing and intermediates patents.
For a generic applicant, the primary regulatory route would be an ANDA with a Paragraph III certification if listed patents remain in force or a Paragraph IV certification if the applicant challenges patent validity, enforceability, or infringement.
Publicly available FDA labeling confirms the approved indication and safety restrictions, but a commercial patent conclusion requires a current Orange Book patent listing review and an examination of terminal disclaimers, patent-term adjustment, pediatric exclusivity, and any litigation history.
When does Zontivity lose exclusivity?
The principal commercial protection for Zontivity has largely expired or become commercially immaterial. Vorapaxar was discovered and developed before its 2014 approval, so composition-of-matter protection did not begin at approval.
A typical small-molecule exclusivity framework is:
| Protection |
Expected effect |
| New chemical entity exclusivity |
Five years from FDA approval, subject to statutory exceptions |
| Listed patent term |
Usually 20 years from the earliest effective nonprovisional filing date |
| Patent-term adjustment |
May extend the nominal patent term |
| Pediatric exclusivity |
Can add six months if granted |
| Method-of-use patents |
May remain relevant only for specifically claimed indications |
| Formulation patents |
Depend on claim scope, validity, and commercial formulation |
Zontivity’s five-year new chemical entity exclusivity period ended in 2019. The key patent barrier was therefore the remaining term of any valid listed patents rather than regulatory exclusivity. No meaningful commercial launch forecast should assume durable branded exclusivity without a current patent-register review.
What formulation patents protect Zontivity?
Zontivity is a conventional oral tablet rather than a complex delivery system. Its formulation barrier is therefore weaker than the barriers associated with long-acting injectables, inhaled products, depot formulations, or biologic delivery technologies.
Potential formulation and solid-state claims may cover:
- Vorapaxar sulfate.
- Specific crystalline or polymorphic forms.
- Tablet compositions.
- Stability characteristics.
- Manufacturing processes for the active pharmaceutical ingredient or finished dosage form.
An ANDA applicant may still need to address formulation or solid-state patents if they are listed and claim the approved product. Those patents are less likely to prevent generic competition when an applicant can use a different salt, polymorph, excipient system, or manufacturing route that remains pharmaceutically equivalent.
Were there Paragraph IV challenges or Zontivity patent litigation?
Zontivity has not generated the level of Paragraph IV litigation associated with major blockbuster antiplatelet products such as Plavix, Brilinta, or Eliquis. The product’s limited revenue opportunity reduced the incentive for extensive patent litigation.
The most relevant generic-entry risks are:
- A Paragraph IV challenge to any remaining listed formulation or method-of-use patent.
- A non-infringement strategy based on a different formulation or manufacturing process.
- A Paragraph III filing that delays approval until patent expiration.
- A commercial decision by generic manufacturers not to enter because of limited demand.
The absence of major public litigation does not establish that every Zontivity patent is invalid or unenforceable. It indicates that the expected commercial return from a challenge has likely been modest.
How strong is the Zontivity patent estate?
Zontivity’s patent estate is commercially weak to moderate when assessed against current market conditions.
| Patent-estate factor |
Assessment |
| Active ingredient |
Historically strong, but age of the asset reduces remaining term |
| Clinical indication |
Narrow, with substantial safety exclusions |
| Formulation |
Conventional oral tablet; limited complexity |
| Manufacturing |
Potential technical barriers, but usually design-aroundable |
| Method of use |
Potentially relevant, but vulnerable to label and induced-infringement issues |
| Biosimilar protection |
Not applicable |
| Generic-entry deterrence |
Low to moderate |
| Litigation value |
Limited by low market size and uncertain demand |
The strongest historical protection was likely associated with the active molecule and its development platform. The weakest protection is the commercial product formulation, which does not require specialized delivery technology.
What is Zontivity’s market position?
Zontivity competes in secondary prevention of atherothrombotic events, but it occupies a narrow segment of the market.
Competitive comparison
| Drug |
Mechanism |
Main commercial advantage |
Main limitation |
| Zontivity |
PAR-1 antagonist |
Long-term secondary prevention in selected prior-MI and PAD patients |
Intracranial bleeding and narrow eligibility |
| Clopidogrel |
P2Y12 antagonist |
Generic, inexpensive, extensive clinical use |
Variable response and drug interactions |
| Ticagrelor |
Reversible P2Y12 antagonist |
Strong evidence in selected acute and chronic coronary settings |
Dyspnea, cost, twice-daily dosing |
| Prasugrel |
P2Y12 antagonist |
Potent platelet inhibition in selected ACS patients |
Not suitable for prior stroke/TIA; bleeding risk |
| Aspirin |
COX-1 inhibitor |
Low cost and broad guideline use |
Residual ischemic risk |
| Rivaroxaban plus aspirin |
Factor Xa inhibition plus antiplatelet therapy |
Evidence in selected stable CAD and PAD patients |
Anticoagulant-related bleeding |
Zontivity’s differentiation is its non-P2Y12 mechanism and evidence for limb-event reduction in peripheral arterial disease. That differentiation has not overcome the availability of low-cost generic antiplatelets and competing vascular-protection regimens.
What is the commercial outlook and revenue projection for Zontivity?
Zontivity has a limited commercial outlook. The product does not have the profile of a growth-stage cardiovascular asset because:
- Its indication is narrow.
- Patients with prior stroke or transient ischemic attack are excluded.
- Bleeding concerns restrict treatment duration and patient selection.
- Generic antiplatelet therapy is widely available.
- Alternative dual-pathway antithrombotic regimens compete for peripheral arterial disease patients.
- There is no major clinical-development program expanding the label.
Base-case projection
| Period |
Commercial expectation |
| 2024-2025 |
Low and declining branded demand; maintenance use in selected patients |
| 2026-2028 |
Generic or discontinued-product economics dominate if supply remains available |
| 2029 onward |
Minimal branded revenue; residual value may persist in limited markets or institutional use |
The base case is annual global revenue below the level required to justify major additional clinical or patent investment. An upside case would require a new clinical indication with a favorable bleeding profile, a niche use in PAD, or evidence showing superiority over established therapy. No such evidence currently supports a high-growth forecast.
What generic launch risks exist for Zontivity?
Generic entry risk is high from a commercial perspective even if regulatory or patent issues remain.
A generic applicant would assess:
- Bioequivalence of the oral tablet.
- Salt and polymorph selection.
- Any remaining Orange Book-listed patents.
- Label carve-outs for protected methods of use.
- Manufacturing complexity.
- The size of the remaining treated population.
- Availability and pricing of comparator antiplatelet therapies.
A generic launch could occur without a large litigation campaign if remaining patents are expired, unlisted, or commercially unattractive to enforce. The greatest barrier may be market economics rather than patent validity.
What geographic markets are relevant to Zontivity?
The United States is the principal reference market for Zontivity because FDA approval established the clearest regulatory and reimbursement pathway. International commercialization has been constrained by regulatory scrutiny of intracranial bleeding and by the availability of alternative antiplatelet therapies.
Geographic value is highest where:
- PAD prevalence is high.
- Long-term secondary prevention is reimbursed.
- Generic antiplatelet prices remain favorable to manufacturers.
- Physicians accept intensified antithrombotic treatment in carefully selected patients.
Geographic expansion is unlikely to create a material revenue inflection without new clinical evidence or a differentiated formulation.
What manufacturing and intellectual-property barriers affect Zontivity?
Vorapaxar manufacturing may involve specialized synthetic intermediates, chiral control, impurity management, and solid-state characterization. Those factors can create technical barriers for an inexperienced manufacturer, but they do not constitute a durable market barrier when:
- The active pharmaceutical ingredient can be sourced from qualified suppliers.
- The finished dosage form is a conventional tablet.
- Alternative process routes are available.
- The product has no biologic comparability burden.
- The demand base is small enough to support contract manufacturing.
The product does not face biosimilar risk. It faces conventional generic-drug risk, which is generally more direct and less expensive to manage than biosimilar competition.
What is the investment and licensing outlook for Zontivity?
A licensing transaction for Zontivity would likely focus on geographic commercialization, supply rights, or a portfolio transaction rather than a major upfront payment for global development.
Potential transaction structures include:
- Low-cost regional commercialization rights.
- Supply-and-distribution agreements.
- Portfolio acquisition with other cardiovascular products.
- Rights tied to PAD-focused clinical evidence.
- Manufacturing transfer or API supply arrangements.
A buyer would need to discount the asset for bleeding-related restrictions, limited prescriber adoption, patent-age risk, and substitution by generic antiplatelet therapies. The strongest licensing rationale would be access to an existing cardiovascular sales infrastructure, not standalone product growth.
Key takeaways
- Zontivity is vorapaxar, an oral PAR-1 antagonist approved by the FDA in 2014.
- Its approved use is limited to secondary prevention in patients with prior myocardial infarction or peripheral arterial disease.
- TRA 2°P-TIMI 50 demonstrated cardiovascular and limb-event benefits but also confirmed important bleeding risks.
- Prior stroke, transient ischemic attack, and intracranial hemorrhage are contraindications.
- New chemical entity exclusivity ended in 2019.
- Zontivity has no active late-stage clinical program that supports a material label expansion.
- Patent protection is less commercially defensible than for complex formulations or biologics.
- Generic-entry risk is high because the product is a conventional oral tablet and demand is limited.
- The commercial outlook is maintenance or decline, with low probability of meaningful revenue growth.
- Any current patent or Orange Book conclusion requires review of the live FDA listing and applicable patent records.
Frequently asked questions
Is Zontivity still being marketed?
Zontivity has limited commercial relevance and may have restricted availability depending on market and supplier status. Current product availability should be distinguished from FDA approval status.
Can patients with a prior stroke take Zontivity?
No. Prior stroke and transient ischemic attack are contraindications under the FDA labeling because of intracranial bleeding risk.
Is vorapaxar a blood thinner?
Vorapaxar is an antiplatelet drug, not a conventional anticoagulant. It inhibits PAR-1-mediated platelet activation.
Does Zontivity have a biosimilar competitor?
No. Zontivity is a small-molecule drug and is subject to generic-drug competition rather than biosimilar competition.
Is Zontivity better than clopidogrel for peripheral arterial disease?
Zontivity demonstrated benefit in selected PAD patients, particularly for limb-related outcomes, but its bleeding risk and cost-benefit profile must be compared with clopidogrel, aspirin, and rivaroxaban-plus-aspirin strategies.
References
- U.S. Food and Drug Administration. (2014). Zontivity (vorapaxar sulfate) prescribing information.
- Morrow, D. A., Braunwald, E., Bonaca, M. P., et al. (2012). Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine, 366(15), 1404-1413.
- Bonaca, M. P., Scirica, B. M., Creager, M. A., et al. (2013). Vorapaxar in patients with peripheral artery disease: Results from TRA 2°P-TIMI 50. Circulation, 127(14), 1522-1529.
- Tricoci, P., Huang, Z., Held, C., et al. (2012). Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. New England Journal of Medicine, 366(1), 20-33.
- ClinicalTrials.gov. (n.d.). TRA 2°P-TIMI 50: Thrombin receptor antagonist for clinical event reduction in acute coronary syndrome. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
